Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

NCT05477615 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Lazertinib
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Jin Hyoung Kang

Collaborators

[object Object]